Familial nephrotic syndrome
MONDO:0002350An instance of nephrotic syndrome that is caused by an inherited modification of the individual's genome.
Also known as: congenital nephrotic syndrome, hereditary nephrotic syndrome
25 clinical trials for this condition and its sub-types, 0 tagged with Familial nephrotic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Familial nephrotic syndrome
-
Nephrotic syndrome 14 3 trials
-
Nephrotic syndrome, type 4 1 trial
-
1 sub-type
- Pierson syndrome 0 trials
-
14 sub-types
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial proliferation 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with diffuse mesangial sclerosis 0 trials
- Familial idiopathic steroid-resistant nephrotic syndrome with minimal changes 0 trials
- Familial steroid-resistant nephrotic syndrome with sensorineural deafness 0 trials
- Focal segmental glomerulosclerosis 1 0 trials
- Nephrotic syndrome, type 10 0 trials
- Nephrotic syndrome, type 11 0 trials
- Nephrotic syndrome, type 12 0 trials
- Nephrotic syndrome, type 13 0 trials
- Nephrotic syndrome, type 2 0 trials
- Nephrotic syndrome, type 3 0 trials
- Nephrotic syndrome, type 6 0 trials
- Nephrotic syndrome, type 8 0 trials
- Nephrotic syndrome, type 9 0 trials
-
Nephrotic syndrome 15 0 trials
-
Nephrotic syndrome 16 0 trials
-
Nephrotic syndrome, IIa 26 0 trials
-
Nephrotic syndrome, type 17 0 trials
-
Nephrotic syndrome, type 18 0 trials
-
Nephrotic syndrome, type 19 0 trials
-
Nephrotic syndrome, type 20 0 trials
-
Nephrotic syndrome, type 21 0 trials
-
Nephrotic syndrome, type 22 0 trials
-
Nephrotic syndrome, type 23 0 trials
-
Nephrotic syndrome, type 24 0 trials
-
New drug hope for rare kidney disease: daratumumab trial launches
Disease control OngoingThis study tests a drug called daratumumab in 40 people with a rare kidney condition called PGNMID, where abnormal proteins damage the kidneys. Participants receive weekly injections for 8 weeks, then every two weeks for another 8 weeks. The goal is to see if the drug can reduce …
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a single injection drug calm the immune attack on kidneys?
Disease control OngoingThis phase 2 trial tests an experimental drug called SGB-9768 in adults with three related kidney diseases: IgA nephropathy, C3 glomerulopathy, and immune complex-mediated membranoproliferative glomerulonephritis. These conditions occur when the immune system deposits proteins in…
Phase 2 • Sponsor: Suzhou Sanegene Bio Inc. • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
CAR-T therapy aimed at tough kidney disease in kids — but trial never started
Disease control CancelledThis was a planned early-stage trial to test whether anti-CD19 CAR-T cells could safely help children with multi-drug resistant nephrotic syndrome, a serious kidney condition. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were co…
Phase 1 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise for controlling rare kidney disorders
Disease control OngoingThis study tests the long-term safety and effectiveness of pegcetacoplan in 100 people with two rare kidney diseases, C3 glomerulopathy and IC-MPGN. Participants previously completed a one-year trial and saw benefit from the drug. The goal is to see if pegcetacoplan can keep redu…
Phase 3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for rare kidney disease patients: early access to pegcetacoplan
Disease control ApprovedThis program provides early access to pegcetacoplan for people aged 12 and older with C3 glomerulopathy or primary IC-MPGN, rare kidney diseases that can lead to kidney failure. Participants must have active disease with significant protein in their urine. The goal is to offer a …
Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC